November 29 - Dec 2, 2016
ICM - International Congress Center Munich
Abstract submission deadline: Monday, June 27
Advance registration deadline: Thursday, June 16
Scientific Committee Co-chairpersonsJean-Charles Soria, Institute Gustave-Roussy, Villejuif, France (EORTC)Lee J. Helman, National Cancer Institute, Bethesda, Maryland, USA (NCI)Levi A. Garraway, Dana-Farber Cancer Institute, Boston, Massachusetts, USA (AACR)
Hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2016 Symposium will bring together around 2000 academics, scientists and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection and the impact of new discoveries in molecular biology.
As a one-of-a-kind Symposium at the forefront of drug development, it will enable participants to apply the latest findings and knowledge in their work and practice. This edition will also build on the success of the previous symposium which was widely praised for the quality of its programme, inspirational contributions and exclusive insights.
EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium website for more information.